T cell stimulation by the human immunodeficiency virus 1 gpl60-derived peptide pl8 presented by H-2D a class I major histocompatibility complex molecules in a cell-free system was found to require proteolytic cleavage. This extracdlular processing was mediated by peptidases present in fetal calf serum. In vitro processing of p18 resulted in a distinct reverse phase high performance liquid chromatography profile, from which a biologically active product was isolated and sequenced. This peptide processing can be specifically blocked by the angiotensin-1 converting enzyme (ACE) inhibitor captopril, and can occur by exposing p18 to purified ACE. The ability of naturally occurring extracellular proteases to convert inactive peptides to T cell antigens has important implications for understanding cytotoxic T lymphocyte responses in vivo, and for rational peptide vaccine design.
CA), and duted with a gradient of 15-30% acetonitrile over 30 rain. The flow rate was I ml/min and the absorbance was monitored at 220 nm. Forty 1-ml fractions were collected, dried down in a Spin-Vac, and resuspended in 200/zl ddonized water. The pooled and unpooled fractions were diluted 1:8 in 0.1% BSA in PBS, filtersterilized and evaluated for functional activity.
Stimulation of the T Cell Hybridoma with Purified Class I. Soluble
H-2D d protein was coated onto Immulon 4 plates (Dynatech Labs., Inc., Chantilly, VA) at 0.1-0.25/.tg/well in 50-p.1 PBS for 2-2.5 h at 37~ The plates were washed twice with 200-/~1 PBS and blocked for 30-60 rain with the incubation medium to be added during the peptide pulsing period.
Peptide and human ~z-microglobulin (~rm) (Calbiochem Corp.) (0.2/zg/well) were added to the incubation media, 0.5% BSA (Sigma Chemical Co. fraction V), OVA (Sigma Chemical Co. grade V), or FCS (Hyclone Laboratories Inc., Logan, UT), to give a final volume of 200 tzl/well, and the plates were incubated at 37~ and 7.5% CO2 for 22-26 h. The plates were then washed twice with PBS and 2 x 104 B4.2.3 T-hybridoma cells (anti-p18 plus H-2D a) (12) were added per well in DMEM supplemented with 10% FCS, 2-mM glutamine, nonessential amino acids, 50/~g/ml gentamicin, and 5 x 10 -s M 2-ME (complete medium). The plates were incubated from 16-20 h at 37~ and 7.5% CO2. The cells were then pulsed with 1-/~Ci [3H]thymidine (ICN Biomedicals, Inc., Costa Mesa, CA), and collected 4-8 h later for counting the amount of incorporated label to evaluate growth inhibition (13) .
Response of T Cell Hybridoma to Cell-surface Class I. H-2D d
positive L cells (2 x 104/well) with peptide, 3T3 neomycin resistance gene transfectant calls, or 3T3 gp160 gene transfectant calls were added to each well with 104 B4.2.3 T-hybridoma cells. After an overnight incubation, 50/zl/well of supernatant was harvested and freeze-thawed. These supernatants were added to 4 x 103 CTLL-2 cells in ILPMI complete medium to give a final volume of 200 ~tl/well. After an 18-h incubation, 1-~Ci [3H]thymidine was added to each well. 4 h later, the CTLb2 cells were collected and counted for incorporated thymidine.
Results and Discussion
The HIV-1 (IIIB) gp160 envelope glycoprotein-derived peptide, p18, is 15 amino acids in length (residues 315-329). It is the immunodominant CTL determinant of gp160 in H-2D d mice (11, 14) , and is also able to sensitize syngeneic cells for lysis by CTL from HIV-l-infected humans (15) . Previous studies of the ability of this peptide to form a stimulatory complex with soluble purified H-2D a molecules in vitro, indicated that two activities of FCS were required for recognition of p18 by a specific T cell hybridoma. One activity was that of/32-m (12, (16) (17) (18) (19) , and the other activity could be provided by OVA. Most batches of BSA were unable to replace this ~2-m-independent effect of FCS. The recent evidence concerning the importance of length in the activity of peptides presented by MHC class I molecules, and the identification of a truncation of p18, p18-I-10 (residues 318-327), with 101-102-fold greater potency of T cell stimulation (T. Takeshita, manuscript in preparation) prompted us to consider the possibility that OVA and FCS were processing p18 to an active, shorter peptide.
Thus, we compared the two peptides of different lengths in our ceU-free system for their functional binding to class I MHC molecules in the presence of BSA, OVA, or FCS (Fig.  1 ). This binding was evaluated through activation of the B4.2.3 pl8-specific T cell hybridoma, measured by growth inhibition (13) . With p18, FCS or OVA was required for significant activation of B4.2.3. In contrast, this activation was decreased by FCS or OVA when p18-I-10 was used. The concentration of p18-I-10 which gave half-maximal stimulation was 10-11 M when added in BSA. This concentration was 101-102-fold less than the half-maximal concentration of p18-I-10 used in FCS, and 103-fold lower than the half-maximal concentration of p18-I-10 when used in OVA.
One possible explanation of these results is that proteolytic enzymes in OVA and FCS degrade the p18 15mer to a smaller active form, and also reduce the active 18-I-10 10mer to an inactive form. To evaluate this hypothesis, we incubated p18 with either OVA or BSA overnight, size-fractionated the small MW peptides away from the OVA or BSA, and analyzed them by reverse-phase HPLC (Fig. 2) . A decrease in the amount, and a slight increase of the retention time of the major peak of p18 in PBS (data not shown) was seen in the OVA-treated peptide, but not in the BSA-treated peptide. The HPLC profile of the OVA-treated p18 also differed from the BSA-treated p18 in amount and retention time of several minor peaks. To determine in which fractions of the OVAtreated p18 the T cell-stimulatory activity eluted, the fractions were assayed for presentation by plate-bound H-2D d. The active growth-inhibiting material was in fractions 26 and 27, eluting later than the p18 major peak. These fractions had very little 220-nm absorbance. The BSA-treated p18 fractions were unable to inhibit the growth of the T cell hybridoma. This observation suggested that a very small fraction of the processed p18 was a highly active peptide, as has been noted for the SV12 peptide and its synthetic contaminants (8) . However, in contrast to the latter case, this active peptide is not a contaminant of the original p18 preparation. The active fractions were pooled and the sequence of the peptide was determined to be XIQRGPGRAFVTI, which is identical to p18 lacking two COOH-terminal residues. A clear peptide sequence was difficult to obtain from the active fraction generated by FCS treatment of p18, probably because of a more complex proteolytic system and contaminating serum peptides. The activity in the OVA appeared to be that of a carboxypeptidase, removing the two COOH-terminal residues from p18.
To identify the carboxypeptidase that processes p18 in FCS, we titrated four carboxypeptidase inhibitors into p18 FCS mixtures, adding them to plate-bound H-2D d. The inhibitots used were potato carboxypeptidase inhibitor (20) , which blocks tissue carboxypeptidases A and B, Plummer's inhibitor (21), which blocks carboxypeptidase N (serum carboxypeptidase B), captopril (22) , which blocks ACE or peptidyl dipeptidase A, and E-64 (23), which blocks cathepsin B (peptidyl dipeptidase B). In the presence of FCS, nanomolar concentrations of captopril blocked p18-dependent stimulation of B4.2.3 (Fig. 3 a) . The blocking of FCS processing of p18 occurred at captopril concentrations 104-10S-fold lower than that of any of the other carboxypeptidase inhibitors. This result suggested ACE (24, 25) , a key regulator of vasoactive peptides, as a major serum processor of p18. Thus, we attempted to process p18 in the absence of serum or OVA using rabbit lung ACE (Fig. 3 b) . The purified ACE was able to process p18 without serum, whereas human carboxypeptidase N was unable to do so. ACE was not required for T cell hybridoma stimulation by p18-I-10, and had some inhibitory effect at high concentrations using both p18 and p18-I-10.
We then evaluated whether the role of ACE in processing p18 for presentation by purified class I molecules would also apply to cell-surface class I molecules. This experiment was done using H-2Dd-transfected L cells as the antigen presenting cells. Peptides p18 and p18-I-10 were titrated in the presence of 10 -s M captopril or Plummer's inhibitor in the presence of medium containing FCS (Fig. 4 a) . The p18 concentration required for half-maximal lymphokine production by the hybridoma was increased by 103-104-fold in the presence of captopril. Captopril had no significant effect on p18-1-10, excluding a direct cellular effect of captopril, and Plummer's inhibitor and E-64 (data not shown) had no effect on p18. In contrast, stimulation of the B4.2.3 hybridoma is not affected by captopril or Plummer's inhibitor when a transfectant cell (11) that expresses the gp160 envelope protein and H-2D a is used as the antigen source (Fig. 4 b) . The data in Fig. 4 a suggest that the ACE extracellular processing demonstrated in the cell-free system is applicable to the cellsurface system. The data in Fig. 4 b suggest that the intracellular processing of the whole antigen is not dependent on an ACE-like activity, or occurs in a cellular compartment inaccessible to captopril.
We have demonstrated that ACE activity is required for the processing of a long peptide (15 residues), and that serum can inactivate a short peptide (10 residues). ACE can remove COOH-terminal dipeptides from many substrates at varying rates. However, peptides with a penultimate proline are not cleaved (25) . The serum processing of a peptide to the correct COOH-terminus for MHC binding would depend on the accumulation of a particular kinetic intermediate in proteolysis. The observation that the active peptide produced by OVA's exopeptidases is a 13mer with the same COOH terminus as the active synthetic peptide 18-1-10, suggests the There are a number of reports in the literature regarding exogenous antigens being recognized by class I-restricted T cells, either through extraceUular processing or specialized class I presenting cells (3, 5, 27, 28) . ACE and other peptidases may trim fragments of soluble antigenic proteins in vivo. The availability of fragments of soluble antigenic proteins may depend on specialized cells that can release proteases or endocytose whole soluble antigen and release fragments (29, 30). Extracellular processing of class I-restricted viral antigenic peptides may lead to generation of noninfected false targets competing for the CTL response against vitally infected cells. This processing may also amplify a CTL response beneficial to the host. Serum enzymes can also lead to degradation of class I antigenic peptides (31) . Pathogens could potentially follow different clinical courses based on their antigenic protein's ability to be processed or degraded extracellularly. PBLs from HIV-infected patients can recognize p18 presented by syngeneic cells (15) . Since ACE inhibitors are currently being used for their hemodynamic benefits in the treatment of HIV cardiomyopathy (32), it will be useful to evaluate patients for the possible immunologic effects of this class of drugs.
A number of laboratories are investigating the use of synthetic peptides for immunization or other immunomodulatory effects. Understanding the specificity of peptide processing in human plasma and other body fluids is of vital importance in the direct design of these synthetic peptides and the possible use of peptidase inhibitors in conjunction with them. This understanding could lead to the development of highly effective vaccines.
